lenalidomide has been researched along with Chromosomal Duplication in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barwick, BG; Bernal, L; Boise, LH; Chen, Z; Dhodapkar, MV; Goyal, S; Gupta, VA; Heffner, LT; Hofmeister, CC; Jaye, DL; Joseph, N; Kaufman, JL; Lonial, S; Nooka, AK; Schmidt, TM; Wu, J | 1 |
| Basset, M; Benner, A; Carpinteiro, A; Dittrich, T; Goldschmidt, H; Hansen, T; Hegenbart, U; Huhn, S; Jauch, A; Kimmich, CR; Müller-Tidow, C; Schönland, SO; Terzer, T; Veelken, K | 1 |
2 other study(ies) available for lenalidomide and Chromosomal Duplication
| Article | Year |
|---|---|
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Duplication; Chromosomes, Human, Pair 1; Dexamethasone; Disease Progression; DNA Copy Number Variations; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Proportional Hazards Models; Treatment Outcome | 2019 |
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Duplication; Chromosomes, Human, Pair 1; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |